- Effect of Puerarin administration on Serum serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1q/TNF-Related Protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (Lp-PLA2) levels.

Serum NOD-like Receptor Protein 3 Inflammasome, C1q/TNF-related Protein 3 and Lipoprotein-associated Phospholipase 2 Levels

  • dan wang 2 Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China
DOI: https://doi.org/10.5937/jomb0-53546
Keywords: Elderly patients withCHD; Pue; NLRP3 inflammasome; CTRP3; Lp-PLA2

Abstract


Introduction: Coronary heart disease (CHD) is a cardiovascular disease with a high incidence in elderly patients. This article aimed to evaluate the clinical efficacy of puerarin (Pue) as an adjuvant therapy in elderly patients with CHD, and the effects of Pue on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1q/TNF-Related Protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (Lp-PLA2) levels.

Method: A total of 118 elderly patients with CHD admitted to Beijing University of Chinese Medicine Third Affiliated HospitaL and 24 induced CHD rat models were enrolled. The controls received conventional treatment, and the study subjects received 5% glucose injection 500mL+Pue injection 0.4g, intravenous drip once a day, 7 days as a course of treatment based on conventional treatment. The improvement of clinical symptoms in patients with CHD and the changes of serum NLRP3 inflammasome, CTRP3 and Lp-PLA2 levels in patients and experimental rats were compared.

Result: Relative to the controls, the study subjects had a reduction in the number of angina episodes and an increase in exercise tolerance. In addition, the serum NLRP3 inflammasome and Lp-PLA2 were distinctly decreased, and the serum CTRP3 was distinctly raised in study subjects and experimental rats. C

onclusion: Pue may improve the inflammatory state and lipid metabolism in patients with CHD by inhibiting NLRP3 inflammasome and regulating the levels of biomarkers such as CTRP3 and Lp-PLA2, thereby reducing symptoms and improving the quality of life.

References

1. Shaya GE, Leucker TM, Jones SR, Martin SS, Toth PP. Coronary heart disease risk: Low-density lipoprotein and beyond. Trends Cardiovasc Med, 2022;32(4):181-194.
2. Sigamani A, Gupta R. Revisiting secondary prevention in coronary heart disease. Indian Heart J, 2022;74(6):431-440.
3. Dam V, Onland-Moret NC, Burgess S, Chirlaque MD, Peters SAE, Schuit E, Tikk K, Weiderpass E, Oliver-Williams C, Wood AM, Tjønneland A, Dahm CC, Overvad K, Boutron-Ruault MC, Schulze MB, Trichopoulou A, Ferrari P, Masala G, Krogh V, Tumino R, Matullo G, Panico S, Boer JMA, Verschuren WMM, Waaseth M, Pérez MJS, Amiano P, Imaz L, Moreno-Iribas C, Melander O, Harlid S, Nordendahl M, Wennberg P, Key TJ, Riboli E, Santiuste C, Kaaks R, Katzke V, Langenberg C, Wareham NJ, Schunkert H, Erdmann J, Willenborg C, Hengstenberg C, Kleber ME, Delgado G, März W, Kanoni S, Dedoussis G, Deloukas P, Nikpay M, McPherson R, Scholz M, Teren A, Butterworth AS, van der Schouw YT. Genetically determined reproductive aging and coronary heart disease: a bidirectional 2-sample mendelian randomization. J Clin Endocrinol Metab, 2022;107(7):e2952-e2961.
4. Foà A, Canton L, Bodega F, Bergamaschi L, Paolisso P, De Vita A, Villano A, Mattioli AV, Tritto I, Morrone D, Lanza GA, Pizzi C. Myocardial infarction with nonobstructive coronary arteries: from pathophysiology to therapeutic strategies. J Cardiovasc Med (Hagerstown), 2023;24(Suppl 2):e134-e146.
5. Schwinger RHG. Secondary prevention for coronary heart disease. MMW Fortschr Med, 2023;165(5):38-41.
6. Gao ML, Zhang ZY, Lai K, Deng Y, Zhao CB, Lu ZL, Geng Q. Puerarin: A protective drug against ischemia-reperfusion injury. Front Pharmacol, 2022;13:927611.
7. Bai YL, Han LL, Qian JH, Wang HZ. Molecular mechanism of puerarin against diabetes and its complications. Front Pharmacol, 2022;12:780419.
8. Zhao LP, Wang L, Zhang DM, Chen YQ, Jin FL. Puerarin alleviates coronary heart disease via suppressing inflammation in a rat model. Gene, 2021;771:145354.
9. Jiang ZL, Cui XN, Qu PR, Shang C, Xiang M, Wang J. Roles and mechanisms of puerarin on cardiovascular disease: A review. Biomed Pharmacother, 2022;147:112655.
10. Xu JW, Tian ZH, Li Z, Du XS, Cui YS, Wang JR, Gao M, Hou YL. Puerarin-Tanshinone IIA suppresses atherosclerosis inflammatory plaque via targeting succinate/HIF-1α/IL-1β axis. J Ethnopharmacol, 2023;317:116675.
11. Qin WD, Guo JH, Gou WF, Wu SH, Guo N, Zhao YP, Hou WB. Molecular mechanisms of isoflavone puerarin against cardiovascular diseases: What we know and where we go. Chin Herb Med, 2022;14(2):234-243.
12. Li JP, Li YN, Yuan XK, Yao DF, Gao ZY, Niu ZY, Wang Z, Zhang Y. The effective constituent puerarin, from Pueraria lobata, inhibits the proliferation and inflammation of vascular smooth muscle in atherosclerosis through the miR-29b-3p/IGF1 pathway. Pharm Biol, 2023;61(1):1-11.
13. Ma JW, Li K. Systemic immune-inflammation index is associated with coronary heart disease: A cross-sectional study of NHANES 2009-2018. Front Cardiovasc Med, 2023;10:1199433.
14. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res, 2021;128(11):1728-1746.
15. Silvis MJM, Demkes EJ, Fiolet ATL, Dekker M, Bosch L, van Hout GPJ, Timmers L, de Kleijn DPV. Immunomodulation of the NLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction. J Cardiovasc Transl Res, 2021;14(1):23-34.
16. Liu DM, Cui XW, Lu R, Hu HJ, Gu GQ. CTRP3 is a coronary artery calcification biomarker and protects against vascular calcification by inhibiting β-catenin nuclear translocation to prevent vascular smooth muscle cell osteogenic differentiation. J Cardiol, 2022;79(4):551-558.
17. Zhang LK, Li ZP, Li N. Serum IMA and LP-PLA2 Levels in patients with coronary heart disease and their correlation with the degree of myocardial ischaemia and their diagnostic value. Emerg Med Int, 2022;2022:1698315.
18. Chen F, Yang WZ, Tan QB, Ni ZI, Zhang SG, Zhou RH, Zhang B. Relationship between severity of coronary artery lesions and levels of Lp-PLA2. J Biol Regul Homeost Agents, 2021;35(6):1919-1922.
19. Zuo QY, Li L, Zhong MJ, Chen GB, Xio JH. Correlation between CYP2C9 gene polymorphism and warfarin dose in Chinese Han population with coronary heart disease. Cell Mol Biol, 2021;67(5):157–163.
20. Boden WE, Marzilli M, Crea F, Mancini GBJ, Weintraub WS, Taqueti VR, Pepine CJ, Escaned J, Al-Lamee R, Gowdak LHW, Berry C, Kaski JC; Chronic Myocardial Ischemic Syndromes Task Force. Evolving management paradigm for stable ischemic heart disease patients: JACC review topic of the week. J Am Coll Cardiol, 2023;81(5):505-514.
21. Bebo A, Jarmul JA, Pletcher MJ, Hasbani NR, Couper D, Nambi V, Ballantyne CM, Fornage M, Morrison AC, Avery CL, de Vries PS. Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study. PLoS One, 2023;18(6):e0285259.
22. Fan CR, Wang QZ, Chen YJ, Ye TT, Fan YC. Puerarin from Pueraria lobate attenuates ischemia-induced cardiac injuries and inflammation in vitro and in vivo: The key role of miR-130a-5p/HMGB2 pathway. Chem Biol Drug Des, 2023;101(4):952-961.
23. Lv JY, Shi SQ, Zhang BX, Xu X, Zheng HR, Li YM, Cui XN, Wu HQ, Song QQ. Role of puerarin in pathological cardiac remodeling: A review. Pharmacol Res, 2022;178:106152.
24. Ding Y, Li WH, Peng S, Zhou GQ, Chen SW, Wei Y, Xu J, Gu HB, Li JY, Liu SW, Liu B. Puerarin Protects against myocardial ischemia/reperfusion injury by inhibiting ferroptosis. Biol Pharm Bull, 2023;46(4):524-532.
25. Wang XY, He K, Ma LL, Wu L, Yang Y, Li YF. Puerarin attenuates isoproterenol-induced myocardial hypertrophy via inhibition of the Wnt/β-catenin signaling pathway. Mol Med Rep, 2022;26(4):306.
26. Sheng GH, Zhou J, Zhang C, Wu CJ, Huang KR, Qin XT, Wu J. Relationship between Lp-PLA2 and in-stent restenosis after coronary stenting: a 3-year follow-up study. Scott Med J, 2021;66(4):178-185.
Published
2025/01/10
Issue
Ahead of print
Section
Original paper

Copyright (c) 2025 dan wang

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.